What is Editas?
Editas Medicine is a biotechnology firm headquartered in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. The company is dedicated to leveraging the power of genome editing technologies to develop a pipeline of medicines aimed at treating individuals afflicted with severe diseases. Their focus on translating cutting-edge scientific advancements into tangible therapeutic solutions positions them at the forefront of genetic medicine innovation.
How much funding has Editas raised?
Editas has raised a total of $257.4M across 3 funding rounds:
Series A
$43M
Series B
$120M
Stock Offering
$94.4M
Series A (2013): $43M with participation from Third Rock Ventures, Polaris Partners, Flagship Pioneering, and Partners Innovation Fund
Series B (2015): $120M led by Boris Nikolic, M.D., Partners Innovation Fund, Deerfield, Casdin Capital, Jennison Associates, T. Rowe Price Associates, Flagship Ventures, Alexandria Venture Investments, Omega Funds, Khosla Ventures, Cowen, Third Rock Ventures, Polaris Partners, Viking Global Investors, Fidelity Management & Research Company, EcoR1 Capital, and Google Ventures
Stock Issuance/Offering (2016): $94.4M, investors not publicly disclosed
Key Investors in Editas
Third Rock Ventures
Third Rock Ventures is a healthcare venture capital firm established in 2007, dedicated to identifying and nurturing disruptive scientific and medical innovations. They focus on building companies that aim to significantly improve patient outcomes through a combination of scientific vision, strategic leadership, and operational expertise.
Polaris Partners
Polaris Partners is a venture capital firm specializing in backing transformative companies within the biotech and healthcare industries. With extensive experience, they collaborate with entrepreneurs to foster growth and develop innovative business solutions.
Flagship Pioneering
Founded in 1999, Flagship Pioneering is a science-driven company that builds and scales businesses aimed at transforming human health and sustainability. They are known for their pioneering approach to company creation and development in the life sciences.
What's next for Editas?
The recent major strategic investment signals a pivotal phase for Editas Medicine, likely enabling accelerated development of its therapeutic candidates and expansion of its research and development capabilities. This infusion of capital is expected to fuel clinical trials, further platform enhancements, and strategic partnerships, driving the company closer to delivering on its mission of creating transformative treatments for patients with serious genetic disorders. The company's trajectory suggests a continued focus on advancing its pipeline through robust scientific execution and strategic financial backing.
See full Editas company page
